EUDA Health Holdings Limited (EUDAW)
| Market Cap | 43.67M -68.1% |
| Revenue (ttm) | 6.82M +70.0% |
| Net Income | -2.77M |
| EPS | -1.48 |
| Shares Out | 1.89M |
| PE Ratio | n/a |
| Forward PE | 10.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,824 |
| Open | 0.0319 |
| Previous Close | 0.0389 |
| Day's Range | 0.0316 - 0.0336 |
| 52-Week Range | 0.0101 - 0.3975 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 19, 2023 |
About EUDAW
EUDA Health Holdings Limited engages in the provision of non-invasive healthcare services primarily in Singapore, Malaysia, and China. It offers bioenergy capsule, stem cell therapy, and CRISPR gene editing treatment services; and supplements. The company also provides property management services. The company is headquartered in Singapore.
News
EUDA Health Holdings Ltd trading halted, volatility trading pause
09:34 EDT EUDA Health (EUDA) Holdings Ltd trading halted, volatility trading pause
EUDA Health Holdings Ltd trading resumes
09:44 EDT EUDA Health (EUDA) Holdings Ltd trading resumes
EUDA Health Holdings Ltd trading halted, volatility trading pause
09:52 EDT EUDA Health (EUDA) Holdings Ltd trading halted, volatility trading pause
EUDA Health Holdings Ltd trading resumes
10:02 EDT EUDA Health (EUDA) Holdings Ltd trading resumes
EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapo...
EUDA Health Holdings Ltd trading halted, volatility trading pause
09:45 EDT EUDA Health (EUDA) Holdings Ltd trading halted, volatility trading pause
EUDA Health Holdings Ltd trading resumes
09:55 EDT EUDA Health (EUDA) Holdings Ltd trading resumes
EUDA Health receives listing noncompliance notice from Nasdaq
EUDA Health (EUDA) received a written notice from the Listing Qualifications Department of Nasdaq on April 23 indicating that the company had failed to maintain a Minimum Market Value of…
EUDA Health Holdings Ltd trading resumes
09:36 EDT EUDA Health (EUDA) Holdings Ltd trading resumes
EUDA Health Holdings Ltd trading halted, volatility trading pause
09:31 EDT EUDA Health (EUDA) Holdings Ltd trading halted, volatility trading pause
EUDA Health Holdings Ltd trading halted, news pending
19:50 EDT EUDA Health (EUDA) Holdings Ltd trading halted, news pending
EUDA Announces Reverse Stock Split of its Ordinary Shares
SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Ma...
EUDA Health price target lowered to $2.75 from $6 at Greenridge
Greenridge analyst William Gregozeski lowered the firm’s price target on EUDA Health (EUDA) to $2.75 from $6 and keeps a Buy rating on the shares. The firm updated its model…
EUDA Health announces repurchase, cancellation of Streeterville warrant
EUDA Health (EUDA) has repurchased and cancelled in full the warrant previously issued to Streeterville Capital. As previously disclosed, the Company entered into a securities purchase agreement dated...
EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant
SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Ma...
EUDA Health announces second amendment to Streeterville warrant agreement
EUDA Health (EUDA) entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital. Under the terms of the Second Warrant Amendment dated January 13, the Compa...
EUDA Health enters convertible loan agreement with Shenzhen Inno
EUDA Health (EUDA) Holdings entered into a convertible loan agreement with Shenzhen Inno Immune. Under the terms of the agreement, EUDA expects to invest up to RMB 6M in two…
EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Ma...
EUDA Health announces amendment to Streeterville warrant agreement
EUDA Health (EUDA) announced that it has entered into an amendment to its previously disclosed warrant agreement with Streeterville Capital. On December 16, 2025, EUDA and Streeterville Capital entere...
EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement
SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malay...
EUDA launches stem cell extraction, cryostorage, clinical delivery platform
EUDA Health (EUDA) Holdings announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune ...
EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital
SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malay...
EUDA Health to launch EUDA Helixe 2.0 in January
EUDA Health (EUDA) Holdings will launch EUDA Helixe 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixe 2.0 introduces enhan...
EUDA Health to Launch EUDA Helixé 2.0 in January 2026
SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Mala...
EUDA Health launches stem cell therapy platform, opens first clinic in Shenzhen
EUDA Health (EUDA) announced an acceleration of its longevity and regenerative medicine strategy with the launch of a stem cell therapy platform and establishment of its first clinic in Shenzhen,…